Faculty Bios

Chairperson

 
Andrew H. Ko, MD
Associate Professor, Division of Hematology/Oncology
University of California, San Francisco

 

Andrew Ko, MD, is Associate Professor in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF) and a member of the Helen Diller Family Comprehensive Cancer Center at UCSF. He also serves as Chairperson of the Gastrointestinal Cancer Site Committee and Scientifi  Protocol Review Committee at the UCSF Comprehensive Cancer Center and has co-directed the second-year medical school course on cancer medicine over the past decade. Dr. Ko’s primary clinical and research interests focus on the development of novel therapies for pancreatic cancer, an area in which he has led multiple clinical trials, both within UCSF and across multiple sites nationwide and overseas. He has also established numerous collaborations with laboratory investigators at UCSF and elsewhere to look at molecular predictors of response to specifi therapies and to analyze circulating tumor cells. Furthermore, he has been actively involved in a clinic-based case-control study funded by National Institutes of Health together with members of UCSF’s Department of Biostatistics and Epidemiology, to identify clinical and molecular risk factors in patients with newly diagnosed pancreatic cancer.

Dr. Ko is a member of the Scientific Program Committee and Specialty Editorial Board for the American Society of Clinical Oncology, sits on several editorial boards for peer-reviewed oncology journals including the Journal of Clinical Oncology, and  is currently a member of the National Cancer Institute’s Pancreatic Cancer Task Force and the National Comprehensive Cancer Network®  Clinical Practice Guidelines in Oncology for Pancreatic Cancer committee. He received a Doctor of Medicine degree at the Johns Hopkins School of Medicine and went on to complete residency training in Internal Medicine at Beth Israel Hospital/ Harvard Medical School, and a fellowship in Medical Oncology at Stanford University Medical Center.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The presenting faculty members have all made the proper disclosures, and the following relationships are relevant:

Andrew H. Ko , MD, reported a financial interest/relationship or affiliation in the form of Consulting fee: Merrimack Pharmaceuticals; Contracted research: Aduro Biosciences; Celgene Corporation; ImClone LLC; Infinity Pharmaceuticals, Inc.; OncoGenex Pharmaceuticals, Inc.; Prism Pharmaceuticals, Inc.; Seattle Genetics, Inc.; Clinical trials research: Genentech, Inc.; Data and Safety Monitoring board  member: Incyte Corporation.

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Linda Gracie-King, MS; Deborah Middleton, MS; and Jocelyn Timko, BS, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.


Faculty

 
Ghassan Abou-Alfa, MD
Associate Professor of the Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

Dr. Ghassan K. Abou-Alfa is an Associate Professor of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York. He specializes in the treatment of gastrointestinal malignancies and in particular, hepato-pancreato-biliary cancers.

Dr. Abou-Alfa’s research is dedicated to finding novel therapies and improving the effectiveness current therapies for hepato-pancreato-biliary cancers, while continuing to understand the basic mechanisms of the diseases and their therapies. He has many publications in the field and has led international teams of investigators. Dr. Abou-Alfa serves as the Chair of the National Cancer Institute Task Force for Hepatobiliary Cancers and the Chair of the AIDS Malignancy Consortium Non-AIDS Defining Malignancies Liver/GI Task Force. He also chairs the hepatocellular carcinoma subgroup of the Alliance cooperative group, and is a cadre member of both the gastrointestinal cancers and pharmacogenomics and population pharmacology committees

Dr. Abou-Alfa earned an MD degree from the American University of Beirut, Lebanon, and completed his post-doctoral training at Yale University School of Medicine.

Ghassan Abou-Alfa, MD, reported a financial interest/relationship or affiliation in the form of Consulting fee (Speaker and Spouse): Aduro BioTech; Array BioPharma; Astellas Pharma US, Inc.; BioAlliance; Boston Scientific Corporation; Boston Therapeutics; Bristol-Myers Squibb Company; CASI Pharmaceuticals, Inc.; Celgene Corporation; Cipla Ltd.; Eli Lilly and Company; Gilead; IntraGen; MedImmune; Merrimack Pharmaceuticals; Momenta Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Onxeo; Pharmacyclics, Inc.; Sanofi-aventis; Silenseed Ltd.; SillaJen; Vicus Therapeutics; Contracted research (Speaker and Spouse): Abbott Laboratories; Amgen, Inc.; Bayer Pharmaceuticals Corporation; Celgene Corporation; Eli Lilly and Company/Imclone; Exelixis, Inc.; Genentech, Inc.; Immunomedics, Inc.; Incyte Corporation; Momenta Pharmaceuticals, Inc.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals; Polaris Pharmaceuticals; Roche; Vicus Therapeutics.


Tanios Bekaii-Saab, MD
Associate Professor, Internal Medicine
Associate Professor, Pharmacology
The Ohio State University
Section Chief, Gastrointestinal Oncology
James Cancer Hospital and Solove Research Institute
Leader, Disease Specific Research Group for Gastrointestinal Oncology
Ohio State University Comprehensive Cancer Center
Columbus

Tanios Bekaii-Saab, MD, joined the faculty at The Ohio State University - Arthur G. James Cancer Hospital and Solove Research Institute in 2002 where he is a tenured Associate Professor of Medicine and Pharmacology and Section Chief for the gastrointestinal cancer program. He is also Chairman of the Gastrointestinal Disease Research Group at The Ohio State University Comprehensive Cancer Center. Dr. Bekaii-Saab’s research interests include experimental therapeutics/translational research focused on gastrointestinal malignancies, and molecular-targeted and immune therapies. He is the Principal Investigator on numerous clinical trials, including studies supported through research grants from the National Cancer Institute (NCI) and the National Comprehensive Cancer Network®  (NCCN®). He is also the recipient of numerous research grants from various industry partners. Dr. Bekaii-Saab received the prestigious NCI Clinical Investigator Team Leadership Award and the American Society of Clinical Oncology Leadership Program Development Award. Additionally, he has been listed in U.S. News and World Report Top Doctors list and is one of the Best Doctors in America.

Dr. Bekaii-Saab is actively involved in a number of professional societies including the American Society of Clinical Oncology, the American Association for Cancer Research, the American Society for Clinical Pharmacology and Therapeutics, and the Alliance cooperative group. He also serves as a member on the NCCN® Colorectal Cancer panel. In addition, he has served as journal editorial board member for over 50 journals such as JNCCN, World Journal of Hepatology, US Oncological Review, and HemOnc Today. He has authored over 100 publications and 130 abstracts in a number of journals including the Journal of Clinical Oncology, Annals of Oncology, and Clinical Cancer Research. Dr. Bekaii-Saab earned a Doctor of Medicine degree from the American University of Beirut in Lebanon and completed a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana. He completed fellowships in clinical pharmacology and experimental therapeutics and hematology/ oncology at Tufts University/New England Medical Center in Boston, Massachusetts.

Tanios Bekaii-Saab, MD, reported a financial interest/relationship or affiliation in the form of Consulting fee:  Amgen, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Genetech, Inc.; Eli Lilly and Company; Contracted research:  Oncolytics Biotech, Inc.


 
 
Gerard C. Blobe, MD, PhD
Professor of Medicine, Pharmacology and Cancer Biology
Duke University Medical Center
Co-Director of the Gastrointestinal Cancer Program
Co-Director of the Solid Tumor Therapeutics Program
Research Director of the Division of Medical Oncology
Duke Cancer Institute
Durham, North Carolina

 

Gerard C. Blobe, MD, PhD, is Professor of Medicine, Pharmacology and Cancer Biology at Duke University School of Medicine in Durham, North Carolina. He is also Co-Director of the Gastrointestinal Cancer Program and Solid Tumor Therapeutics Programs for the Duke Cancer Institute and Research Director of the Division of Medical Oncology. Dr. Blobe’s basic and translational laboratory at Duke University Medical Center investigates the role of tumor growth factor-beta superfamily signaling in cancer biology, focusing on mechanisms for their dichotomous tumor promoting and suppressing function, as well as investigating strategies for targeting these pathways. Clinically, he specializes in the treatment of patients with colorectal and pancreatic cancer, and in phase 1 therapeutics development.

Dr. Blobe has published over 85 peer-reviewed manuscripts, including articles in The New England Journal of Medicine, the Journal of Clinical Oncology, Blood, Science, the Journal of Clinical Investigation, Proceedings of the National Academy of Science, The EMBO Journal, The FASEB Journal, and the Journal of Biological Chemistry, and has given over 80 lectures and grand rounds presentations, including presentations at the American Association for Cancer Research and FASEB Conferences. He currently serves as an Associate Editor for The Journal of Clinical Investigation, has served on the editorial board for The Journal of Biological Chemistry, and was a standing member of the National Institutes of Health Molecular Oncogenesis Study Section.

Dr. Blobe’s lab has received peer-reviewed funding from the National Institutes of Health/National Cancer Institute, the Department of Defense, the American Cancer Society, and the American Heart Association. For his research efforts, Dr. Blobe has been awarded a V Foundation Scholar Award, a Research Scholar Award from the American Cancer Society, the 2005 Gertrude B. Elion Award for Cancer Research from the American Association for Cancer Research, and was inducted into the American Society of Clinical Investigation.

Gerard Blobe, MD,PhD, reported a financial interest/relationship or affiliation in the form of Speakers' bureau:  Genentech - A member of the Roche Group.


 
 
Gabriela Chiorean, MD
Associate Professor of Medicine
University of Washington School of Medicine
Seattle Cancer Care Alliance
Seattle

 

Elena Gabriela Chiorean, MD, is Associate Professor of Medicine at the University of Washington and Associate Member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center in Seattle. Her clinical practice serves patients with colorectal and pancreatic cancers, and her research expertise is in early phase development of clinical trials focusing on molecular signaling pathways to foster novel clinical and translational research in gastrointestinal malignancies.

Dr. Chiorean has served on several national committees such as the American Society of Clinical Oncology Developmental Therapeutics Program Committee, the National Cancer Institute Gastrointestinal Cancer Steering Committee –Pancreatic Cancer Task Force, the panel of the National Comprehensive Cancer Network®  Clinical Practice Guidelines for Pancreatic Cancer, and  has been Co-Chair of the Gastrointestinal Cancers Committee for the Hoosier Cancer Research Network. She has authored multiple publications and given many presentations at major national and international meetings, and has been a principal or co-investigator on several Department of Defense, National Institutes of Health, and institutional research grant initiatives. Dr. Chiorean received a Doctor of Medicine degree from the University of Medicine and Pharmacy Cluj-Napoca, Romania, and completed a residency at William Beaumont Hospital in Royal Oak, Michigan.

E. Gabriela Chiorean, MD, reported a financial interest/relationship or affiliation in the form of Consulting fee:  Genentech, Inc.; Contracted research:  Celgene Corporation; Genentech, Inc.; Prism Pharmaceuticals, Inc.; Spectrum Pharmaceuticals, Inc.


 
 
Steven J. Cohen, MD
Chief of GI Medical Oncology
Co-Leader of the GI Cancer Service Line
Fox Chase Cancer Center
Philadelphia, Pennsylvania

 

Steven Cohen, MD, is Chief of Gastrointestinal Medical Oncology and Co-Leader of the gastrointestinal (GI) cancer service line at Fox Chase Cancer Center in Philadelphia, Pennsylvania. In addition to his GI cancer responsibilities, Dr. Cohen serves as the Program Director for the Temple University Hospital/Fox Chase Cancer Center hematology/oncology fellowship program. He also is Chief Medical Officer for Fox Chase Cancer Center Partners, overseeing medical oncology at affiliated hospitals within the Fox Chase network.

He is a member of the committee for the National Comprehensive Cancer Network Clinical Practice Guidelines®  in Oncology for pancreatic adenocarcinoma; the Eastern Cooperative Oncology Group, where he is the representative on the National Cancer Institute Pancreatic Cancer Task Force; and the American Society of Clinical Oncology, where he is also a member of the test materials development committee and a member of the scientific program committee, gastrointestinal (colorectal) cancer track.

In 2010, he received the National Cancer Institute clinical investigator team leadership award and in 2013, he graduated from the American Society of Clinical Oncology leadership development program. Dr. Cohen is on the editorial board for the Journal of Gastrointestinal Cancer and is a peer reviewer for Cancer Chemotherapy and Pharmacology, International Journal of Cancer, Clinical Cancer Research, Journal of Clinical Oncology, Oncology, Cancer, Clinical Colorectal Cancer, Clinical Advances in Hematology and Oncology, Expert Opinion on Drug Discovery, Journal of the National Comprehensive Cancer Network, Annals of Oncology, and Annals of Surgical Oncology. He received a Doctor of Medicine degree from State University of New York at
Stony Brook.

Steven J. Cohen, MD, reported a financial interest/relationship or affiliation in the form of Consulting fee:  Celgene Corporation; Merrimack Pharmaceuticals.


 
 
Syma Iqbal, MD
Assistant Professor of Medicine
Assistant Program Director
Oncology Fellowship Program
USC Norris Comprehensive Cancer Center and Hospital
Los Angeles, California

 

Syma Iqbal, MD, is currently Assistant Professor in the Division of Oncology and Assistant Program Director of the Oncology Fellowship Program at the University of Southern California (USC) Norris Comprehensive Cancer Center and Hospital in Los Angeles, California. She is also educational officer of the Division of Oncology and co-director of the Liver Cancer Program at USC.

Dr. Iqbal has several research initiatives in progress and has received grants for 15 clinical studies. In addition to numerous authored articles, book chapters, and abstracts that have been published in medical journals and textbooks, she has frequently lectured at major conferences nationwide. Dr. Iqbal serves as an Assistant Editor for Women’s Oncology Review and sits on the Clinical Investigations Committee and the Pharmacy Review Committee at the USC Keck School of Medicine. She received a Doctor of Medicine degree from the USC Keck School of Medicine, where she also completed a fellowship in hematology  and oncology.

Syma Iqbal, MD, reported a financial interest/relationship or affiliation in the form of Speakers' bureau:  Bristol-Myers Squibb Company; Celgene Corporation; Novartis Pharmaceuticals Corporation.


 
 
George P. Kim, MD
Assistant Professor of Oncology
Mayo Clinic College of Medicine
Consultant, Department of Hematology and Oncology
Mayo Clinic – Jacksonville
Jacksonville, Florida

 

George P. Kim, MD, is a Medical Oncologist, specializing in gastrointestinal (GI) oncology, at 21st Century Oncology and the University of Florida Cancer Center in Jacksonville. An international expert in the field of GI oncology lecturing throughout the world, Dr. Kim has been a Principal Investigator of several GI cancer trials conducted through the North Central Cancer Treatment Group, Phase 2 Consortium, and Mayo Clinic Cancer Center involving colorectal, pancreatic, and hepatocellular cancers. He was also a Principal Investigator in Mayo Clinic Pancreas Cancer SPORE and is funded to study predictive markers of gemcitabine activity.

Dr. Kim serves on United States Intergroup Pancreas and Colon Cancer Task Force Committees. He has published numerous reports on the treatment of these cancers and on the discovery of predictive markers. He has authored numerous peer- reviewed manuscripts and multiple book chapters. Dr. Kim serves on patient advocacy boards for stomach and pancreatic cancer. After receiving a medical degree from the University of Vermont, College of Medicine, Dr. Kim completed an internship and residency at the Johns Hopkins Hospital. He attended the National Cancer Institute for his medical oncology fellowship, where he conducted laboratory research involving microsatellite instability and analyzed archived specimens from several National Surgical Breast and Bowel Project colorectal cancer phase 3 trials. This published work helps define the predictive and prognostic roles of high-degree microsatellite instability.

George P. Kim, MD, reported a financial interest/relationship or affiliation in the form of Consulting fee:  Celgene Corporation; Speakers' bureau:  Celgene Corporation.


 
Eileen M. O’Reilly, MD
Associate Professor of Medicine
Weill Cornell Medical College
Associate Director, Clinical Research
Memorial Sloan Kettering Cancer Center
New York, New York

 

Dr. Eileen M. O’Reilly serves as the Associate Director for Clinical Research for the David M. Rubenstein Center for Pancreas Cancer at Memorial Sloan Kettering Cancer Center (MSKCC) and is an Associate Professor of Medicine at Weill Medical College of Cornell University in New York City.

Pancreatic and hepatobiliary malignancies are the major focus of Dr. O’Reilly’s research and clinical activities. Research initiatives include integration of molecular and genetic-based therapies for the treatment of pancreas cancer along with development of adjuvant and neoadjuvant therapies and identification of biomarkers that maybe used to select therapy. Dr. O’Reilly teaches and mentors oncology fellows (national and international), junior faculty, residents, and house-staff and has numerous teaching and other awards. She is the Principal Investigator of multiple phase 1, 2, and 3 trials in pancreas cancer and has authored/co-authored approximately 180 articles, editorials, and book chapters. Dr. O’Reilly’s other responsibilities at MSKCC include Associate Chairperson of the Institutional Review & Privacy Board, member of the Research Council, and Chair of the Continuing Medical Education committee. Nationally, Dr. O’Reilly is the Chair of the National Cancer Institute Pancreas Task Force, a member of the Alliance GI Core committee, and serves on the Scientific Advisory Board of the Pancreatic Cancer Action Network, National Comprehensive Cancer Network pancreas guidelines committee, Board of the National Pancreas Foundation, and American Society of Clinical Oncology Integrated Media and Technology committee.

Dr. O’Reilly earned an MD degree from Trinity College (Dublin University) in Ireland and completed residency training in Ireland and fellowship training at MSKCC.

Eileen M. O'Reilly, MD, reported a financial interest/relationship or affiliation in the form of Consulting fee (Speaker and Spouse): Aduro BioTech; Array BioPharma; Astellas Pharma US, Inc.; BioAlliance; Boston Therapeutics; Bristol-Myers Squibb Company; CASI Pharmaceuticals, Inc.; Celgene Corporation; Cipla Ltd.; Eli Lilly and Company; Gilead; IntraGen; MedImmune; Merrimack Pharmaceuticals; Momenta Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Onxeo; Pharmacyclics, Inc.; Sanofi-aventis; Silenseed Ltd.; SillaJen; Vicus Therapeutics; Contracted research (Speaker and Spouse): Abbott Laboratories; Amgen, Inc.; Bayer Pharmaceuticals Corporation; Celgene Corporation; Eli Lilly and Company/Imclone; Exelixis, Inc.; Genentech, Inc.; Immunomedics, Inc.; Incyte Corporation; Momenta Pharmaceuticals, Inc.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals; Polaris Pharmaceuticals; Roche; Vicus Therapeutics.


 
 
Weijing Sun, MD, FACP
Division and Co-Director of the
Gastrointestinal Cancer Center of Excellence
University of Pittsburgh School of Medicine
UPMC Cancer Pavilion
Pittsburgh, Pennsylvania

 

Weijing Sun, MD, FACP, is a Medical Oncologist, Professor of Medicine, Director of the Gastrointestinal Cancer Disease Section  in the Division of Hematology-Oncology, and Co-Director of the University of Pittsburgh Medical Center Gastrointestinal Cancer Center of Excellence in Pennsylvania.

Dr. Sun is a member of the American Medical Association, the American Society of Clinical Oncology, the American Association of Cancer Research, the Eastern Cooperative Group of Oncology Gastrointestinal Cancer Core Committee, the American College of Physicians – Internal Medicine, the National Cancer Institute Gastrointestinal Cancer Steering Committee Hepatobiliary Task Force, and serves on the American Society of Clinical Oncology scientific program and membership committee. In addition, Dr. Sun has been recognized on the U.S. News & World Report American top doctors list.

Dr. Sun has authored many publications, including original clinical research articles, reviews, and invited editorial comments in a variety of peer-reviewed journals. He has also written chapters as a gastrointestinal oncology expert for several medical textbooks, including the Textbook of Gastroenterology. Dr. Sun has had more than 70 publications. He is a member of the editorial board and review committee for several professional journals, including Clinical Colorectal Cancer, the Journal of Clinical Gastroenterology, the Journal of Clinical Oncology, Cancer, Diseases of the Colon & Rectum, Cancer Biology and Therapy, Expert Opinion on Investigational Drugs, Pharmacogenomics, Gastroenterology, Expert Review of Anticancer Therapy, and the American Journal of Hematology-Oncology. Dr. Sun received a Doctor of Medicine degree from Shanghai Medical College, Fudan University, in Shanghai. He completed a residency in internal medicine at Loyola University Medical Center in Maywood, Illinois, and a hematology-oncology fellowship at the University of Pennsylvania in Philadelphia.

Weijing Sun, MD, FACP, reported a financial interest/relationship or affiliation in the form of Consulting fee:  Celgene Corporation.


 
 
David Tuveson, MD, PhD
Roy J. Zuckerberg Professor of Cancer Research
Deputy Director of the Cancer Center
Cold Spring Harbor Laboratory
Cold Spring Harbor, New York

 

David A. Tuveson, MD, PhD, is the Roy J. Zuckerberg Professor of Cancer Research and Deputy Director of the Cancer Center of Cold Spring Harbor Laboratory in New York. He also continues to practice medical oncology with an adjunct appointment at Memorial Sloan Kettering Cancer Center in New York, New York. His awards include the Rita Allen Scholarship and the Jan Waldenström Award. 

Dr. Tuveson obtained Doctor of Medicine and Doctorate degrees from Johns Hopkins University in Baltimore, Maryland. He then completed a residency at Brigham and Women’s Hospital in Boston, Massachusetts, and a medical oncology fellowship at Dana-Farber/Partners Cancer Care. While in Boston, Dr. Tuveson co-developed KIT inhibitors for gastrointestinal stromal tumors with Dr. George Demetri. Simultaneously, he generated several widely used mouse cancer models with Tyler Jacks. As an independent investigator, his laboratory team generated the first mouse models of ductal pancreatic cancer at the University of Pennsylvania. Subsequently, Dr. Tuveson was recruited to the University of Cambridge to develop preclinical and clinical therapeutic strategies for pancreatic cancer. In Cambridge, his laboratory team identified a variety of parameters that limit therapeutic efficacy in pancreatic cancer, including poor drug delivery and survival factors in the microenvironment. These findings are currently undergoing clinical evaluation. 

David Tuveson, MD, PhD, reported a financial interest/relationship or affiliation in the form of Consulting fee:  Celgene Corporation; Chugai Pharmaceutical Co., Ltd.; Merrimack Pharmaceuticals; Pfizer, Inc.; Contracted research:  FibroGen, Inc.


 
 
Andrea Wang-Gillam, MD, PhD
Assistant Professor
Washington University School of Medicine
St. Louis, Missouri

 

Andrea Wang-Gillam, MD, PhD, is an Assistant Professor specializing in gastrointestinal malignancies at Washington University School of Medicine in St. Louis, Missouri. Dr. Wang-Gillam’s research interest is the area of preclinical evaluation and an early phase clinical trial of novel therapies targeting RAS downstream pathways in pancreatic cancer, and she is a Principal Investigator for multiple pancreatic cancer clinical trials. She is a member of the American Society of Clinical Oncology, where she served on the scientific committee from 2010 to 2012.

Dr. Wang-Gillam received Doctor of Medicine and Doctorate degrees from the University of Arkansas for Medical Science in Little Rock, where she also completed a residency in internal medicine and a fellowship in hematology/oncology.

Andrea Wang-Gillam, MD, PhD, reported a financial interest/relationship or affiliation in the form of Speakers' bureau:  Merrimack Pharmaceuticals.


 
 
Brian M. Wolpin, MD, MPH
Co-Director, Pancreatic Tumor Center 
Dana-Farber Cancer Institute 
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

 

Dr. Brian M. Wolpin is the Co-Director of the Pancreatic tumor Center within Dana-Farber Cancer Institute.  He received his medical degree from Harvard Medical School in 2001. Dr. Wolpin subsequently completed his residency in Internal Medicine at Brigham and Women's Hospital, and his fellowship in Medical Oncology at the Dana-Farber Cancer Institute. He joined the staff of DFCI and Brigham and Women's Hospital in 2007, where he is a medical oncologist and clinical investigator in the Center for Gastrointestinal Oncology. Dr. Wolpin’s research focuses on biomarkers and novel therapeutics in gastrointestinal malignancies, and mechanisms by which lifestyle factors interact with malignant risk and progression.

Brian M. Wolpin, MD, has no real or apparent conflicts of interest to report.